Libo Pharma Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-221.94	-147.8	-46.41
Depreciation & Amortization	22.79	17.57	4.89
Other Amortization	0.13	0.1	0.12
Stock-Based Compensation	29.42	23.6	0.5
Other Operating Activities	0.25	-0.2	-3.17
Change in Accounts Receivable	-	0.23	3.61
Change in Accounts Payable	13.49	-1.03	4.19
Change in Other Net Operating Assets	-6.37	-10.94	0.31
Operating Cash Flow	-162.24	-118.47	-35.96
Capital Expenditures	-1.74	-1.36	-0.05
Sale (Purchase) of Intangibles	-1.21	-172.24	-0.17
Investment in Securities	-	-	44.45
Other Investing Activities	-0.08	-0.08	-
Investing Cash Flow	-3.02	-173.68	44.23
Long-Term Debt Repaid	-	-1.15	-1.05
Net Debt Issued (Repaid)	-1.39	-1.15	-1.05
Issuance of Common Stock	128.06	493.47	1.08
Financing Cash Flow	126.67	492.32	0.03
Net Cash Flow	-38.59	200.16	8.3
Free Cash Flow	-163.97	-119.84	-36.01
Free Cash Flow Per Share	-4.01	-3.20	-1.36
Cash Interest Paid	0.05	0.05	0.07
Cash Income Tax Paid	-	0.2	0.23
Levered Free Cash Flow	-	-239.68	-
Unlevered Free Cash Flow	-	-239.65	-
Change in Working Capital	7.12	-11.73	8.11

Source: S&P Global Market Intelligence. Standard template. Financial Sources.